Safety and Efficacy of pALG in Conditioning Regimen for HLA-Matched Sibling HSCT in Patients With SAA or Hematological Malignancies ( pALG-MSDHSCT )
Safety and Efficacy of Anti-human T-cell Porcine Immunoglobulin in Conditioning Regimens for HLA Sibling Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia (SAA)/Hematological Malignancies
This study is a single-arm clinical study designed to evaluate the safety and efficacy of p-ALG in HLA sibling identical Hematopoietic stem cell transplantation( HSCT) conditioning regimens for severe aplastic anemia (SAA)/hematologic malignancies in patients diagnosed with hematologic malignancies or sSAA requiring allogeneic HSCT from our center. Graft anti-host disease (GVHD) is the most common and severe complication of allogeneic HSCT, which significantly affects survival and quality of life. Even among recipients of HLA-identical sibling HSCT (MSD-HSCT), the incidence of acute GVHD( aGVHD) and chronic GVHD (cGVHD) reaches 40-50% and 30-70%, respectively.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
This study was designed to explore the safety and efficacy of anti-human T cell porcine immunoglobulin p-ALG in the conditioning regimen of HLA sibling allogeneic hematopoietic stem cell transplantation for severe aplastic anemia (SAA)/hematological malignancies in 60 patients.
(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days.
The enrollment time was 24 months, and patients were followed up for 24 months to evaluate long-term efficacy.
Pharmacokinetics, inflammatory cytokines and active antibodies were measured on day 0 before pALG administration and on days 3, 5, 7, 14, 21, 28 and 60 after p-ALG administration.
Routine follow-up after transplantation was performed to assess implantation and chimerism rate, immune reconstitution, infection prevention, graft versus host disease prevention, treatment-related mortality, and overall survival.
Blood routine, urine routine, liver and kidney function, clinical manifestations and ECOG score were recorded on 28± 7,60 ± 7,90 ± 7,180 ± 7,270 ± 7,360 ± 7,450 ± 7,540 ± 7,630 ± 7,720 ±7 days after transplantation; implantation rate, OS, aGVHD, cGVHD, CMV, EB virus and other infections were recorded.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Erlie Jiang
- Numer telefonu: +86-15122538106
- E-mail: jiangerlie@ihcams.ac.cn
Kopia zapasowa kontaktu do badania
- Nazwa: Xin Chen
- Numer telefonu: +86-13920985705
- E-mail: chenxin@ihcams.ac.cn
Lokalizacje studiów
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Chiny, 300020
- National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dziecko
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Patients with severe aplastic anemia (type I/II) or hematologic malignancies undergoing HLA-matched sibling hematopoietic stem cell transplantation.
Opis
Inclusion Criteria
- age: no age limit for severe aplastic anemia type I or II, patient or donor age>40 years for hematologic malignancies;
- gender: no gender limit;
- sibling identical hematopoietic stem cell transplantation;
- fair general status, ECOG score <2 points;
- no age limit for severe aplastic anemia, no gender limit; patient or donor age>40 years for hematologic malignancies.
Exclusion Criteria:
- uncontrolled viral, bacterial and fungal infections (disease progression during antifungal therapy);
- pregnant and lactating patients or patients unable to use appropriate contraception during treatment;
- psychiatric disorders or other medical conditions unable to comply with study treatment and monitoring requirements;
- known seropositive for HIV, active hepatitis B, active hepatitis C virus, or syphilis;
- history of tumor and treatment for any tumor within the past 3 years;
- Prior hematopoietic stem cell transplantation;
- Active heart disease, defined as one or more of the following: ① Long QTc syndrome or QTc interval>480ms;② Complete left bundle branch block, degree II or III atrioventricular block;③ History of arrhythmia requiring medication or severe clinical symptoms;④ American New York Heart Association classification ≥II; ④ Left ventricular ejection fraction less than 50%; History of myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, history of clinically serious pericardial disease, or ECG evidence of acute ischemic or active conduction system abnormalities within 6 months prior to enrollment.
- Subjects considered unsuitable for enrollment by the investigator.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Liczba grup / kohort
Kohorty i interwencje
Grupa / KohortaGrupa / Kohorta |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
p-ALG cohort
(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days. |
(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Incidence of acute graft-versus-host disease (aGVHD)
Ramy czasowe: within 100 days after hematopoietic stem cell infusion
|
aGVHD was evaluated via the modified Glucksberg criteriahematopoietic stem cell transplantation, diagnosed and graded according to standard criteria. |
within 100 days after hematopoietic stem cell infusion
|
|
Incidence of chronic graft-versus-host disease (cGVHD)
Ramy czasowe: 5 years after hematopoietic stem cell transplantation
|
cGVHD was defined in accordance with the National Institutes of Health (NIH) guidelines |
5 years after hematopoietic stem cell transplantation
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
1-year implantation rate
Ramy czasowe: 1-year
|
The rate of primary and secondary poor engraftment of neutrophils and platelets within 1 year |
1-year
|
|
Overall survival rate
Ramy czasowe: 5 years after hematopoietic stem cell transplantation
|
All-cause mortality from hematopoietic stem cell infusion to the last follow-up |
5 years after hematopoietic stem cell transplantation
|
|
Rejection (AA) or recurrence (malignant)
Ramy czasowe: 5 years after hematopoietic stem cell transplantation
|
Rejection (AA) or recurrence (malignant) from hematopoietic stem cell infusion to the last follow-up |
5 years after hematopoietic stem cell transplantation
|
|
Incidence of fungal infection
Ramy czasowe: 2 years after hematopoietic stem cell infusion
|
Incidence of fungal infection from hematopoietic stem cell infusion to the last follow-up |
2 years after hematopoietic stem cell infusion
|
|
Incidence of cytomegalovirus infection
Ramy czasowe: 2 years after hematopoietic stem cell infusion
|
Incidence of cytomegalovirus infection from hematopoietic stem cell infusion to the last follow-up |
2 years after hematopoietic stem cell infusion
|
|
Incidence of Epstein-Barr virus infection
Ramy czasowe: 2 years after hematopoietic stem cell infusion
|
Incidence of Epstein-Barr virus infection from hematopoietic stem cell infusion to the last follow-up |
2 years after hematopoietic stem cell infusion
|
|
Transplant-related mortality
Ramy czasowe: 5 years after hematopoietic stem cell infusion
|
Non-relapse/progression-related death occurring within 100 days after hematopoietic stem cell infusion |
5 years after hematopoietic stem cell infusion
|
|
Drug-related toxic and side effects from hematopoietic stem cell infusion to the last
Ramy czasowe: 2 years after hematopoietic stem cell infusion
|
Drug-related toxic and side effects from hematopoietic stem cell infusion to the last follow-up |
2 years after hematopoietic stem cell infusion
|
Współpracownicy i badacze
Sponsor
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- IIT2026106
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .